Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,518Revenue $M778Net Margin (%)15.2Z-Score19.4
Enterprise Value $M2,352EPS $2.3Operating Margin %23.6F-Score5
P/E(ttm))24.4Cash Flow Per Share $1.4Pre-tax Margin (%)24.0Higher ROA y-yN
Price/Book3.810-y EBITDA Growth Rate %0Quick Ratio5.0Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %22.7Current Ratio5.4Lower Leverage y-yY
Price/Cash Flow19.2y-y EBITDA Growth Rate %-32.2ROA % (ttm)13.8Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)15.7Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M71.1ROI % (ttm)21.6Gross Margin Increase y-yN

Gurus Latest Trades with MYGN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MYGNRichard Snow 2014-12-31 Reduce-0.3%$32.01 - $39.48
($35.39)
$ 35.400%Reduce -21.54%827,803
MYGNJoel Greenblatt 2014-12-31 Reduce-0.11%$32.01 - $39.49
($35.44)
$ 35.40-0%Reduce -34.58%568,865
MYGNKen Fisher 2014-12-31 Buy 0.01%$32.01 - $39.48
($35.39)
$ 35.400%New holding88,333
MYGNAndreas Halvorsen 2014-09-30 Sold Out -0.23%$35.44 - $40.41
($37.28)
$ 35.40-5%Sold Out0
MYGNJoel Greenblatt 2014-09-30 Reduce-0.12%$35.44 - $40.41
($37.28)
$ 35.40-5%Reduce -22.18%869,531
MYGNJohn Burbank 2014-09-30 Sold Out -0.01%$35.44 - $40.41
($37.28)
$ 35.40-5%Sold Out0
MYGNRichard Snow 2014-06-30 Reduce-0.96%$33.1 - $42.21
($37.18)
$ 35.40-5%Reduce -39.96%1,091,227
MYGNJohn Griffin 2014-06-30 Sold Out -0.38%$33.1 - $42.21
($37.18)
$ 35.40-5%Sold Out0
MYGNAndreas Halvorsen 2014-06-30 Buy 0.23%$33.1 - $42.21
($37.18)
$ 35.40-5%New holding1,330,294
MYGNJean-Marie Eveillard 2014-06-30 Sold Out -0.03%$33.1 - $42.21
($37.18)
$ 35.40-5%Sold Out0
MYGNJohn Burbank 2014-06-30 Buy 0.01%$33.1 - $42.21
($37.18)
$ 35.40-5%New holding16,676
MYGNJohn Griffin 2014-03-31 Buy 0.38%$20.79 - $38.17
($30.6)
$ 35.4014%New holding1,000,000
MYGNRichard Snow 2014-03-31 Add0.37%$20.79 - $38.17
($30.6)
$ 35.4014%Add 18.11%1,817,401
MYGNThird Avenue Management 2014-03-31 Sold Out -0.13%$20.79 - $38.17
($30.6)
$ 35.4014%Sold Out0
MYGNJean-Marie Eveillard 2014-03-31 Buy 0.03%$20.79 - $38.17
($30.6)
$ 35.4014%New holding284,826
MYGNRonald Muhlenkamp 2013-12-31 Sold Out -2.3%$20.79 - $30.65
($25.36)
$ 35.4028%Sold Out0
MYGNRichard Snow 2013-12-31 Add1.29%$20.79 - $30.65
($25.36)
$ 35.4028%Add 10989.60%1,538,685
MYGNJoel Greenblatt 2013-12-31 Add0.18%$20.79 - $30.65
($25.36)
$ 35.4028%Add 36.27%1,316,314
MYGNThird Avenue Management 2013-12-31 Buy 0.13%$20.79 - $30.65
($25.36)
$ 35.4028%New holding328,314
MYGNJoel Greenblatt 2013-09-30 Add0.32%$24.396 - $31.8
($28.51)
$ 35.4019%Add 74.78%965,987
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MYGN is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


MYGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
King Gary A.Exec. VP International Ops 2014-11-03Sell6,568$39.95-11.01view
Evans James SCFO 2014-09-30Sell21,850$38.99-8.82view
Evans James SCFO 2014-09-24Sell8,790$37.98-6.4view
Evans James SCFO 2014-09-23Sell110,463$37.89-6.18view
LANCHBURY JERRY SChief Scientific Officer 2014-07-14Sell20,000$39.85-10.79view
MELDRUM PETER DPresident & C.E.O. 2014-07-14Sell24,000$39.5-10view
HENDERSON JOHN TDirector 2014-06-05Sell5,000$35.7-0.42view
Rogers Ronald S.Exec VP Corp Communications 2014-05-09Sell12,500$36.01-1.28view
MARSH RICHARD ME.V.P., General Counsel 2014-04-30Sell30,000$41.8-14.95view
MARSH RICHARD ME.V.P., General Counsel 2014-04-23Sell31,516$39.8-10.68view

Press Releases about MYGN :

    Quarterly/Annual Reports about MYGN:

    News about MYGN:

    Articles On GuruFocus.com
    Chuck Royce Comments on Myriad Genetics Oct 08 2014 
    Chuck Royce’s Royce Premier Fund Second Quarter 2014 Manager Commentary Oct 08 2014 
    Why I Bought Myriad Genetics (MYGN) Apr 28 2014 
    Scott Black, Delphi Management Recommends Stocks Nov 19 2013 
    Surfing for Billionaire Bargains Sep 23 2013 
    Baron Funds Comments on Myriad Genetics Inc. Jun 06 2013 
    RS Investments' Value Fund First Quarter 2012 Mutual Fund Commentary Apr 17 2012 
    Chuck Royce Buys Hawkins Inc., Myriad Genetics, and Fairchild Semiconductor Jul 07 2011 
    Myriad Genetics Inc. Reports Operating Results (10-Q) May 05 2010 
    Myriad Genetics Inc. (MYGN) CFO James S Evans sells 8,400 Shares Mar 12 2010 

    More From Other Websites
    Goldman Sachs Cuts Myriad Genetics To Sell, Ups Alere Mar 26 2015
    Myriad Poised on Portfolio Strength Despite Y/Y Downfall in Q2 - Analyst Blog Mar 23 2015
    Myriad Announces Prolaris(R) Test Biopsy Results From EMPATHY-P Study at European Association of... Mar 20 2015
    Myriad Announces Prolaris(R) Test Biopsy Results From EMPATHY-P Study at European Association of... Mar 20 2015
    Myriad and BioMarin Expand Collaboration to Evaluate myChoice HRD(TM) as a Companion Diagnostic for... Mar 17 2015
    Myriad and BioMarin Expand Collaboration to Evaluate myChoice HRD(TM) as a Companion Diagnostic for... Mar 17 2015
    Myriad Genetics Unveils Simoa-based Immunoassay Services - Analyst Blog Mar 09 2015
    Myriad RBM Launches New Immunoassay Services Based on the Ultrasensitive Simoa(TM) Platform Mar 05 2015
    Myriad RBM Launches New Immunoassay Services Based on the Ultrasensitive Simoa(TM) Platform Mar 05 2015
    Myriad Publishes myPath(TM) Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology Mar 04 2015
    Myriad Publishes myPath(TM) Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology Mar 04 2015
    Myriad Genetics to Present at the Barclays Global Healthcare Conference Mar 03 2015
    Myriad Genetics to Present at the Barclays Global Healthcare Conference Mar 02 2015
    What Falling Estimates & Price Mean for Myriad Genetics (MYGN) - Tale of the Tape Mar 02 2015
    Heavy News Day For Several Biotech Stocks Feb 25 2015
    Myriad Board Approves $200 Million Increase in Share Repurchase Program Feb 25 2015
    MYRIAD GENETICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 24 2015
    Iridian bumps up position in Myriad Genetics Feb 17 2015
    GeneDx, Inc. and its Parent BioReference Labs Announce Settlement of Their Cancer Gene Testing... Feb 17 2015
    MYRIAD GENETICS INC Financials Feb 10 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Antoniy
    ReplyAntoniy - 1 year ago
    hs
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK